CN1167682C - 毒蕈碱拮抗剂 - Google Patents

毒蕈碱拮抗剂 Download PDF

Info

Publication number
CN1167682C
CN1167682C CNB008130795A CN00813079A CN1167682C CN 1167682 C CN1167682 C CN 1167682C CN B008130795 A CNB008130795 A CN B008130795A CN 00813079 A CN00813079 A CN 00813079A CN 1167682 C CN1167682 C CN 1167682C
Authority
CN
China
Prior art keywords
etoac
compounds
formula
compound
ch2cl2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008130795A
Other languages
English (en)
Chinese (zh)
Other versions
CN1374949A (zh
Inventor
Jw
J·W·克拉德
�Ƴ�
J·A·科茨洛夫斯基
S·W·麦坎比
M·W·米勒
ά
S·F·维斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN1374949A publication Critical patent/CN1374949A/zh
Application granted granted Critical
Publication of CN1167682C publication Critical patent/CN1167682C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB008130795A 1999-09-22 2000-07-05 毒蕈碱拮抗剂 Expired - Fee Related CN1167682C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40139199A 1999-09-22 1999-09-22
US09/401,391 1999-09-22

Publications (2)

Publication Number Publication Date
CN1374949A CN1374949A (zh) 2002-10-16
CN1167682C true CN1167682C (zh) 2004-09-22

Family

ID=23587566

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008130795A Expired - Fee Related CN1167682C (zh) 1999-09-22 2000-07-05 毒蕈碱拮抗剂

Country Status (14)

Country Link
EP (1) EP1214299B1 (enExample)
JP (1) JP2003509494A (enExample)
CN (1) CN1167682C (enExample)
AR (1) AR025459A1 (enExample)
AT (1) ATE264301T1 (enExample)
AU (1) AU5786300A (enExample)
CA (1) CA2384018C (enExample)
CO (1) CO5180624A1 (enExample)
DE (1) DE60009931T2 (enExample)
ES (1) ES2215055T3 (enExample)
HK (1) HK1043590A1 (enExample)
MX (1) MXPA02003136A (enExample)
PE (1) PE20010649A1 (enExample)
WO (1) WO2001021590A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
CN1301972C (zh) * 2001-10-10 2007-02-28 先灵公司 作为毒覃碱拮抗剂的哌啶化合物
JPWO2004069828A1 (ja) * 2003-02-04 2006-05-25 三菱ウェルファーマ株式会社 ピペリジン化合物およびその医薬用途
EP2533645B1 (en) 2010-02-09 2016-07-27 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
JP6478923B2 (ja) 2013-02-07 2019-03-06 ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ ムスカリンｍ４受容体アゴニストとしてのピペリジン−１−イル及びアゼピン−１−イルカルボキシレート
CN105142623A (zh) 2013-03-15 2015-12-09 艾吉因生物股份有限公司 用于改善认知功能的方法和组合物
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
CN107810002B (zh) 2015-05-22 2021-01-05 艾吉因生物股份有限公司 左乙拉西坦的延时释放药物组合物
HK1253029A1 (zh) 2015-11-06 2019-06-06 Neurocrine Biosciences, Inc. 作为毒蕈碱性受体4(m4)拮抗剂用於治疗神经系统疾病的n-[2-(1-苄基哌啶-4-基)乙基]-4-(吡嗪-2-基)-哌嗪-1-甲酰胺衍生物及相关化合物
EP4069367B1 (en) 2019-12-06 2024-05-15 Neurocrine Biosciences, Inc. Muscarinic receptor 4 antagonists and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691323A (en) * 1995-05-12 1997-11-25 Merck & Co., Inc. Muscarine antagonists
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
DE69919171T2 (de) * 1998-06-30 2005-08-04 Schering Corp. Muskarin-rezeptor antagonisten
US6066636A (en) * 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists

Also Published As

Publication number Publication date
CA2384018A1 (en) 2001-03-29
HK1043590A1 (zh) 2002-09-20
AR025459A1 (es) 2002-11-27
ES2215055T3 (es) 2004-10-01
AU5786300A (en) 2001-04-24
JP2003509494A (ja) 2003-03-11
EP1214299B1 (en) 2004-04-14
DE60009931T2 (de) 2005-04-07
DE60009931D1 (de) 2004-05-19
CN1374949A (zh) 2002-10-16
CA2384018C (en) 2010-01-12
ATE264301T1 (de) 2004-04-15
PE20010649A1 (es) 2001-06-19
WO2001021590A1 (en) 2001-03-29
CO5180624A1 (es) 2002-07-30
EP1214299A1 (en) 2002-06-19
MXPA02003136A (es) 2002-09-30

Similar Documents

Publication Publication Date Title
CN1273451C (zh) 哌啶mch拮抗剂及其治疗肥胖症的用途
CN1025999C (zh) 咪唑并[4，5-b]喹啉氧烷酰胺的制备方法
CN1163484C (zh) 4-芳酰基-哌啶-ccr-3受体拮抗剂ⅲ
CN1061977C (zh) 芳基取代的杂环
CN1111529C (zh) 作为神经激肽拮抗剂的哌嗪子基衍生物
CN1639159A (zh) N－氨基乙酰基－吡咯烷－2－腈和它们作为ddp－iv抑制剂的用途
CN1422269A (zh) 1h－咪唑并吡啶衍生物
CN1845921A (zh) 金刚烷和氮杂双环－辛烷及壬烷衍生物、其制备方法及其作为dpp－iv抑制剂的用途
CN1141043A (zh) 非肽类速激肽受体拮抗剂
CN1474810A (zh) 取代脲,神经肽yy5受体拮抗剂
CN1146559C (zh) 毒蕈碱性拮抗剂
CN1426412A (zh) 新化合物
CN1684952A (zh) 用于治疗趋化因子介导的疾病的新的哌啶衍生物
CN1067889A (zh) 取代的n-(1-烷基-3-羟基-4-哌啶基)苯甲酰胺的制备方法
CN1633414A (zh) 化合物
CN1167682C (zh) 毒蕈碱拮抗剂
CN1050122C (zh) 苯并咪唑类,含有这些化合物的药物 组合物和它们的制备方法
CN1756740A (zh) 具有2,6－二取代苯乙烯基的含氮杂环衍生物
CN1798744A (zh) 作为nmda/nr2b拮抗剂的3－氟－哌啶化合物
CN1111528C (zh) 用作神经激肽拮抗药的哌嗪衍生物
CN1322196A (zh) 作为速激肽受体拮抗剂的萘甲酰胺
CN1738800A (zh) 用于治疗雄激素依赖性疾病的3型17β－羟基类固醇脱氢酶抑制剂
CN1234026A (zh) 用作神经激肽拮抗剂的哌嗪并衍生物
CN1144788C (zh) 双环血管加压素激动剂
CN1875017A (zh) 取代的4－氨基－1－(吡啶基甲基)哌啶化合物的萘－1,5－二磺酸盐

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee